NETCast

In this episode of NETCast, we explore two increasingly important, and often underrecognized, aspects of neuroendocrine tumor care: hereditary risk assessment and long-term systemic complications, including carcinoid heart disease.Hosted by Dr. Daniel Halperin and featuring experts in genetic counseling and cardio-oncology, the discussion examines how multidisciplinary NET care teams are evolving beyond traditional oncology models to better support patients across the full continuum of disease.Together, the panel discusses hereditary syndromes, integrating genetic counseling into NET care, recognizing cardiac complications earlier, survivorship considerations, and the importance of communication across multidisciplinary care teams. The conversation also highlights how comprehensive NET programs are increasingly expanding to address the broader systemic and long-term needs of patients living with neuroendocrine tumors.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, we explore the patient and caregiver experience beyond the clinic walls and examine what truly patient-centered care looks like within the neuroendocrine tumor community. Hosted by Dr. Daniel Halperin and featuring leaders from the Neuroendocrine Tumor Research Foundation and Neuroendocrine Cancer Foundation, this conversation focuses on the emotional realities of living with NETs, caregiver advocacy, the importance of community and peer support, and how healthcare teams can better support patients and families throughout the disease journey. Together, the panel shares practical insights and personal perspectives on building trust, reducing isolation, and improving quality of life in rare disease care.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Recorded live at the NANETS Columbus Regional Conference, this episode of NETCast explores the multidisciplinary strategies that drive long-term tumor control in patients with advanced neuroendocrine tumors (NETs).Hosted by Drs. Jordan Cloyd and Bhavana Konda, the discussion brings together experts in medical oncology, surgical oncology, and gastroenterology to examine how treatment decisions evolve over the course of a patient's disease. Rather than focusing on a single intervention, the conversation highlights the importance of balancing systemic therapy, surgery, endoscopic management, quality of life, and patient goals through coordinated multidisciplinary care.Through practical discussion and real-world perspectives, the panel explores treatment sequencing, the evolving role of cytoreductive surgery, when less invasive management may be appropriate, and how multidisciplinary tumor boards help navigate complex clinical decisions. Together, the panel shares insights into how collaboration across specialties leads to more thoughtful, individualized care and better long-term outcomes for patients living with advanced neuroendocrine tumors.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of NETCast, host Dr. Emil Lou is joined by a multidisciplinary panel of experts and a patient advocacy perspective to explore one of the most nuanced aspects of neuroendocrine tumor care: how physicians communicate uncertainty when the data are limited, evolving, or open to interpretation.Featuring perspectives from medical oncology, surgical oncology, nuclear medicine, and patient advocacy, the discussion examines the real-world challenges of navigating gray areas in NET care where multiple treatment paths may be reasonable and patient preferences play a critical role. The panel discusses how clinicians approach conversations when evidence is incomplete, communicate risk and treatment options, manage differing opinions within multidisciplinary teams, and build trust with patients facing complex decisions.Together, the group offers candid reflections and practical insights on balancing science, communication, and compassion in modern NET care.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this live recording from the Nashville Regional, we will explore the real-world impact of multidisciplinary NET specialty centers, particularly for patients initially diagnosed or managed in community settings. What structurally changes when a patient transitions from community-based care to an academic institution? And further, what distinguishes a general academic center from a dedicated NET specialty center?This conversation will examine how multidisciplinary tumor board functions as the operational engine behind complex decision-making, the role of pathology reassessment, referral timing, access to specialized imaging and therapies, and how community and specialty centers can collaborate to optimize outcomes for patients with neuroendocrine tumors.The focus will be on systems of care and collaboration, rather than on a specific therapy or guideline update.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Este podcast médico presenta una discusión entre los Drs. Sarimar Agosto, Alejandro Román-González y Camilo Jiménez sobre el manejo del feocromocitoma y paraganglioma. Manejo multidisciplinario esencial (endocrinología, oncología, cirugía, genética, radiología nuclear). Referir pacientes a centros de excelencia. Cada caso requiere individualización del tratamiento según progresión, localización tumoral y estado global del paciente. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This NETCast episode features Dr. Uday Grewal hosting a discussion with Drs. Aman Chauhan, Renuka Iyer, and Shagufta Shaheen on the complexities of hybrid neuroendocrine cancers. The panel explores transformation cases, mixed histology, and emerging DLL3-targeted therapies with lung cancer and CAR-T expertise.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This NETCast episode from the 2025 NANETS Symposium features Dr. Theodora Dimitra hosting a discussion with Drs. Alexandria Phan, Po H. Ear, Dawn Quelle, and Andrew Bellizzi on a range of hot topics. The panel discusses challenging NET clinical scenarios including biomarkers, GLP-1 medications, and surgical decision-making.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETCast features Dr. Thorvardur Halfdanarson (Mayo Clinic oncologist) and Burt Rosen (patient advocate) discussing artificial intelligence's role in transforming healthcare, particularly for NET patients. Both guests agree AI represents a truly transformative shift—not just another overhyped technology—with potential to revolutionize drug discovery, clinical trial design, and most importantly, move medicine from population-based treatment to individualized care. They also discuss key ethical considerations such as data ownership, patient consent for AI use in care, and ensuring models are trained on diverse populations to avoid amplifying existing biases.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode of NETcast features a "presidential panel" of three distinguished NANETS leaders: Dr. Jennifer Chan (president 2025, Dana-Farber), Dr. Simran Singh (incoming president, Sunnybrook), and Dr. Thorvardur Halfdanarson (president emeritus, Mayo Clinic). The discussion covers transformative developments in NET management over the past decade, including radiopharmaceuticals, targeted therapies, and the recognition that NETs may be less rare than previously thought. The experts explore the future of alpha and beta particle therapy retreatment protocols, challenges in biomarker development, and the importance of treatment sequencing given disease heterogeneity. The panel also discusses the importance of mentorship and the welcoming nature of the NET community in nurturing early-career researchers, while acknowledging that future progress will likely come through incremental advances and optimal treatment sequencing rather than single breakthrough therapies.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.